Bufalin Inhibits the Differentiation and Proliferation of Cancer Stem Cells Derived from Primary Osteosarcoma Cells through Mir-148a

Cellular Physiology and Biochemistry

Volumn 36, Issue 3, 2015, Pages 1186-1196

  Chang, Yuewen ^a   Zhao, Yongfang ^a   Gu, Wei ^a   Cao, Yuelong ^a   Wang, Shuqiang ^a   Pang, Jian ^a   Shi, Yinyu ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Bufalin; Cancer Stem Cells; MicroRNAs; Osteosarcoma

Indexed keywords

BUFALIN; DNA METHYLTRANSFERASE 1; MICRORNA; MICRORNA 148A; PROTEIN P27; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BUFADIENOLIDE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; MIRN148 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHINESE MEDICINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIMARY CULTURE; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BUFANOLIDES; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICINE, CHINESE TRADITIONAL; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

EID: 84933566679     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430289     Document Type: Article

References (43)

1. Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6.
2. Ottaviani G, Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3-13.
3. Ek ET, Dass CR, Choong PF: Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol 2006;60:1-8.
4. Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-1085.
5. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32:423-436.
6. Ta HT, Dass CR, Choong PF, Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009;28:247-263.
7. Luo XJ, Tang DG, Gao TL, Zhang YL, Wang M, Quan ZX, Chen J: MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem 2014;34:2180-2188.
8. Xu H, Liu X, Zhao J: Down-regulation of miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem 2014;33:1547-1556.
9. Xu G, Wang J, Jia Y, Shen F, Han W, Kang Y: MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1. Cell Physiol Biochem 2014;33:1329-1339.
10. Pan W, Wang H, Jianwei R, Ye Z: MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem 2014;33:402-412.
11. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037.
12. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, Olive D: Human acute myeloid leukemia CD34+/CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000;60:4403-4411.
13. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
14. Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G, Vento R: Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 2009;219:301-313.
15. Wang L, Park P, Lin CY: Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 2009;8:543-552.
16. Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, Gao J, Wang H, Zhang Y: Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells 2013;31:433-446.
17. Martins-Neves SR, Lopes AO, do Carmo A, Paiva AA, Simoes PC, Abrunhosa AJ, Gomes CM: Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 2012;12:139.
18. Chang Y, Zhao Y, Zhan H, Wei X, Liu T, Zheng B: Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells. Tumour Biol 2014;35:1075-1082.
19. Han KQ, Huang G, Gu W, Su YH, Huang XQ, Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2007;13:3374-3379.
20. Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 1998;16:779-787.
21. Yeh JY, Huang WJ, Kan SF, Wang PS: Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003;54:112-124.
22. Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, Zhang J, Liu Y: PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 2009;20:59-64.
23. Wang J, Yin JQ, Jia Q, Shen JN, Huang G, Xie XB, Zou CY: [Bufalin induces apoptosis in osteosarcoma U-2OS and U-2OS methotrexate 300-resistant cell lines in vitro]. Zhonghua Zhong Liu Za Zhi 2010;32:734-738.
24. Jovanovic M, Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene 2006;25:6176-6187.
25. van Jaarsveld MT, Wouters MD, Boersma AW, Smid M, van Ijcken WF, Mathijssen RH, Hoeijmakers JH, Martens JW, van Laere S, Wiemer EA, Pothof J: DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. Mol Oncol 2014;8:458-468.
26. Xu M, Jin H, Xu CX, Bi WZ, Wang Y: MiR-34c inhibits osteosarcoma metastasis and chemoresistance. Med Oncol 2014;31:972.
27. Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 2014;33:12.
28. Ziyan W, Shuhua Y, Xiufang W, Xiaoyun L: MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol 2011;28:1469-1474.
29. Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F: microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 2010;24:1363-1369.
30. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28:4065-4074.
31. Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, Yang T, Liu W: CD133 expression in osteosarcoma and derivation of CD133(+) cells. Mol Med Rep 2013;7:577-584.
32. Di Fiore R, Fanale D, Drago-Ferrante R, Chiaradonna F, Giuliano M, De Blasio A, Amodeo V, Corsini LR, Bazan V, Tesoriere G, Vento R, Russo A: Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness. J Cell Physiol 2013;228:1189-1201.
33. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, Llombart-Bosch A, Cleton-Jansen AM: Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011;91:1195-1205.
34. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM: Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A 2011;108:18708-18713.
35. Gazdar AF, Gao B, Minna JD: Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer 2010;68:309-318.
36. Schilsky RL: Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010;9:363-366.
37. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG: Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011;29:1916-1923.
38. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, Lieftucht A, Mazumder A, Milloy J, Shaw PM, Swank D, Wang J, Berndt ER, Goodsaid F, Palmer MC: Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011;10:817-833.
39. Nana-Sinkam SP, Croce CM: MicroRNAs as therapeutic targets in cancer. Transl Res 2011;157:216-225.
40. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 2012;72:1865-1877.
41. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA: Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 2011;204:138-146.
42. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009;2:34.
43. Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, Badidi E, Taranta M, Cinti C: Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One 2014;9:e95596.